Relief of Discomfort

IceWave Research

Studies Summary:

What is the IceWave Patch?

According to the clinical summaries, the LifeWave IceWave patch is a non-transdermal, light-reflecting phototherapy device designed to be placed on specific acupuncture points. Instead of introducing chemical painkillers or drugs into the body, the patches act as passive reflectors that use natural body heat to send specific infrared wavelengths back into the skin, helping optimize cellular bioelectric signaling and support natural pain relief.

Key Findings & What They Mean

  • Rapid Boost in Bioelectric Energy Potential: Electromyographic testing showed that applying the patches produces an immediate increase in bioelectric muscular energy potential (up to 100% within seconds under physical stress), helping restore normal electrical activity in fatigued or stressed muscle tissue.

  • Supporting Nervous System Balance: By stimulating key acupuncture points, the patches help increase tissue electrical conductivity, calm the nervous system, and encourage overall autonomic balance and stress reduction.

  • Clearing Biofield Congestion: Biofield and thermal imaging scans indicated that patch use helps unblock localized energy congestion (notably around areas like the solar plexus), supporting a balanced internal energy flow.

  • Drug-Free and Non-Invasive Relief: Because the patches contain only natural organic crystals (amino acids, sugars, and water) and rely entirely on light reflection, they deliver their physiological effects without any chemical or drug absorption.

Clinical Studies:

Study Title: Osteoarthritis Double-Blind Placebo Controlled LifeWave Med Pain Relief Study (French Multicentric Trial - ANSM #2012-A00838-35 / Study #12E1421)

  • Study Type / Design: Multicentric, double-blind, randomized, placebo-controlled trial across two parallel groups.

  • Sample Size & Demographics: 100 adult participants (analyzed in two groups of 50 active and 50 placebo; mean age 59 years, age range 30–70; 73 females, 27 males) across 5 medical centers in France (Lyon, Marcy, Marseille, St. Priest) presenting with acute and chronic nociceptive pain (arthrosis, post-surgery, traumatology).

  • Intervention / Testing Period: Cutaneous application of the active LifeWave Med 2-patch system (IceWave) versus placebo 2-patch system applied for 1 hour at acupuncture and nerve points. Pain assessed at baseline (t0), 5 minutes, 15 minutes, and 1 hour post-application.

  • Key Metrics Measured: Subjective visual analog pain scale (EVA 0–100 mm) and adverse event safety monitoring.

  • Primary Results & Findings: 1 hour post-application, the active IceWave patch group demonstrated a statistically significant 65% reduction in pain (mean decrease of -41.4 mm on EVA scale, \(p < 0.0001\)) compared to a 23% reduction (-13.3 mm) in the placebo group. The difference in pain reduction between active and placebo patches at 1 hour was 41% (-28 mm on EVA, \(p = 0.0288\) against the 15 mm primary endpoint benchmark). 94% of participants wearing active patches experienced pain improvement at 1 hour compared to 48% with placebo (\(p < 0.0001\)). Zero adverse events occurred.

Osteoarthritis Double-Blind Placebo Controlled LifeWave Med Pain Relief Study.pdf

Study Title: Randomized, Placebo-Controlled Study on the Effects of IceWave Patches on the Reduction of Pain

  • Study Type / Design: Double-blind, randomized, placebo-controlled 7-day longitudinal trial.

  • Sample Size & Demographics: 105 completed adult participants (51 in experimental active group, 54 in control placebo group; age range 24–84 years, mean age ~53) recruited across 2 integrative medicine/acupuncture clinics.

  • Intervention / Testing Period: Daily patch wear over 7 days using the Cross/Clock Method (dark patch on maximal pain center, white patch rotated across 4 clock positions) following a 5-day to 2-week pain medication washout period. Pain recorded daily at baseline and 10 minutes post-application.

  • Key Metrics Measured: Combined Numeric Rating Scale (NRS), Verbal Descriptor Scale (VDS), and Faces Pain Scale (FPS) (0–10 visual analog scale).

  • Primary Results & Findings: The active patch treatment group achieved a statistically significant greater reduction in pain over 7 days compared to the placebo control group (GLM repeated measures \(p < 0.0001\); independent t-test \(p < 0.005\)). On Day 1, active patch wearers experienced a 57% pain reduction compared to 34% in the control group (placebo effect). Over Days 2 through 7, active patch subjects maintained a 43% to 50% pain reduction, whereas control group pain relief regressed back to 13%–25%.

Randomized, Placebo-Controlled Study on the Effects of IceWave Patches on the Reduction of Pain..pdf

Study Title: Double-Blind, Placebo-Controlled Clinical Efficacy Evaluation of a Patch to Soothe Knee Pain (Essex Testing Clinic Panel #09361)

  • Study Type / Design: Double-blind, randomized, placebo-controlled 5-day home-use trial.

  • Sample Size & Demographics: 62 adult participants (31 using Active IceWave X, 31 using Placebo IceWave Y; age range 38–74 years; 7 males, 55 females) presenting with self-perceived arthritic knee pain (minimum baseline score \(\ge 5\) on 0–9 scale).

  • Intervention / Testing Period: 2 days of patch wear (placed on acupuncture points UB53 or Kid10 near knee). Pain evaluated on Day 1 (pre-treatment baseline), Day 3 (1st patch), and Day 4 (2nd patch) across 4 daily timepoints.

  • Key Metrics Measured: 10-point self-perceived arthritic knee pain scale (0 = no pain, 9 = severe pain).

  • Primary Results & Findings: Active IceWave X patches produced statistically highly significant reductions in arthritic knee pain on Day 3 (up to 28.4% reduction, \(p < 0.001\)) and Day 4 (up to 26.8% reduction, \(p < 0.001\)). On Day 4, active IceWave X delivered more than double the level of pain reduction compared to placebo IceWave Y at every evaluation timepoint (\(p < 0.05\)). Prior to bed on Day 4, 77% of active patch wearers reported pain improvement compared to 61% in placebo.

Double-Blind-Placebo-Controlled-Clinical-Efficacy-Evaluation-of-a-Patch-to-Soothe-Knee-Pain.pdf

Study Title: Case Studies on the Effect of LifeWave Energy Enhancer, IceWave, and Glutathione Patches on Human Energy Field (World Peace Centre Study)

  • Study Type / Design: Double-blind, randomized, placebo-controlled biofield imaging trial.

  • Sample Size & Demographics: 120 total adult participants (50 IceWave active, 50 Glutathione active, 20 placebo control; ages 21–70; chronic pain for ~6 months).

  • Intervention / Testing Period: Patches worn for 12 to 24 hours placed on pain areas using the Cross Method (IceWave) or P6 wrist point (Glutathione).

  • Key Metrics Measured: Polycontrast Interference Photography (PIP biofield pixel color density), Gas Discharge Visualization (GDV biophotonic emission), Electro-Interstitial Scan (EIS bio-impedance), Electro Sound Level Meter (ESM), and Chakra Temperature scanning.

  • Primary Results & Findings: 88% to 90% of subjects in the active IceWave group demonstrated positive biofield and energetic shifts (\(p < 0.01\) to \(p < 0.0001\)), showing unblocking of solar plexus and navel chakras, replacement of red low-energy congestion with green/violet healing frequencies, reduced muscle spasms, and decreased oxidative stress markers (MDA, SOD2). By contrast, 80% of placebo control subjects exhibited no change.

LifeWave Patches Research 2009 - IceWave and Glutathione.pdf

LifeWave-Research-Study-World-Peace-Centre.pdf

Effects of LifeWave Ice Wave Patches on Human Biofield.pdf

Study Title: Open-Label Pain Study Comparing the Effects of the IceWave® Pain Patches to the Regular Treatment of Various Pain Medications

  • Study Type / Design: Open-label, dual-center, crossover trial comparing IceWave patches against prescription/OTC pain medications.

  • Sample Size & Demographics: 35-37 elderly participants (28 females, 7 males; ages 60–100; mean age ~76) with persistent musculoskeletal pain taking daily scheduled pain medications (Tylenol, Advil, Vicodin, Morphine, Fentanyl, Tramadol, etc.).

  • Intervention / Testing Period: 10-day crossover protocol evaluating 5 days of IceWave patch application versus 5 days of regular pain medication regimens.

  • Key Metrics Measured: Universal Pain Assessment Tool (UPAT 0–10), Infrared (IR) Thermal Imaging (°C), Patient Specific Functional Scale (PSFS), and Functional Activities Pain Checklist (FAPC).

  • Primary Results & Findings: IceWave patch application achieved a 44.1% reduction in UPAT pain scores at 1 hour (from 5.72 to 3.20, \(p < 0.001\)) and a 44.4% reduction at 5 days (from 5.72 to 3.18, \(p < 0.001\)). By comparison, 5 days of prescription/OTC pain medication achieved only a 32.0% pain reduction (from 5.72 to 3.88, \(p < 0.05\)). Thermal imaging showed a statistically significant 2.5% IR temperature reduction at 1 hour post-patch (-1.4°C cooling, \(p < 0.05\)), whereas 5 days of pain medication caused a 0.05% increase in IR temperature (inflammation).

Open-label Pain Study Comparing the Effects of the IceWave Pain Patches to the Regular Treatment of Various Pain Medications.pdf

Study Title: Effect of IceWave® Organic Nanoscale Patches on Reduction of Musculoskeletal Pain (Palm Beach Clinical Study)

  • Study Type / Design: Open-label, dual-site pretest-posttest pilot study (subjects served as own controls).

  • Sample Size & Demographics: 40 completed adult subjects (16 males, 24 females; ages 20–85; 50% Caucasian, 50% Hispanic) suffering from acute or persistent neuromuscular/musculoskeletal pain (baseline pain score \(\ge 4\)).

  • Intervention / Testing Period: IceWave patches applied daily (worn 12 hours/day over 5 days) using the Clock Method. Pain evaluated at baseline, 1h and 3h on Day 1, and 1h on Days 2–5.

  • Key Metrics Measured: Universal Pain Assessment Tool (UPAT / VAS 0–10).

  • Primary Results & Findings: Mean pain score decreased from 6.08 at baseline to 3.03 at Day 1, Hour 1 (\(p < 0.0001\), 100% statistical power), and down to 1.40 by Day 5 (\(p < 0.0001\)). By Day 1, 100% of subjects experienced pain relief 1 hour post-application. By Day 5, 77.5% of subjects achieved a pain reduction of 4 or more levels, with mean pain reaching 1.4 (near-complete pain resolution). Zero adverse events occurred.

Effect of IceWave Organic Nanoscale Patches on Reduction of Musculoskeletal Pain.pdf

Study Title: Infrared Thermal Imaging Quantifies the Efficacy of IceWave® Patches in Musculoskeletal Pain Relief in Horses

  • Study Type / Design: Open-label veterinary clinical trial.

  • Sample Size & Demographics: 38 horses of varying ages and breeds presenting with mild to severe back pain and musculoskeletal abnormalities.

  • Intervention / Testing Period: Patches placed on painful back areas (identified via veterinary acupuncture palpation and thermal imaging) and worn for 24 hours.

  • Key Metrics Measured: High-resolution digital medical infrared thermal imaging (°C) and veterinary acupuncture palpation pain scale (1–10).

  • Primary Results & Findings: Statistical analysis of both infrared thermal imaging data and veterinary acupuncture palpation scores revealed a statistically highly significant reduction in equine back pain and inflammation (\(p < 0.0001\), 100% statistical power). Patches produced a marked cooling effect in hyperthermic inflamed areas and a warming/perfusion effect in hypothermic areas. Horse owners noted calmer behavior, increased mobility, and improved overall attitude.

(See Study Report #2: Infrared Thermal Imaging Quantifies the Efficacy of IceWave Patches in Musculoskeletal Pain Relief in Horses) in...
IceWave Series of 8 Clinical Study Summaries.pdf

Study Title: LifeWave Scientific Study by Means of an NM4 Gauge (Italian Electromyography Study)

  • Study Type / Design: Controlled physiological study evaluating superficial neuromuscular electrical potentials.

  • Sample Size & Demographics: 117 adult participants (39 detailed in analytical tables) presenting with acute and chronic muscular contractures, joint tension, and pain (cervical, lumbar, shoulder, knee, foot, eye).

  • Intervention / Testing Period: IceWave patches applied using the Clock Method; evaluated before and immediately after patch placement.

  • Key Metrics Measured: NM4 4-channel surface electromyography (superficial EMG measuring microvolt neuromuscular potential) and self-perceived pain scale (0–10).

  • Primary Results & Findings: IceWave patch application produced an almost immediate moderation of muscular contractions, spasms, and muscle tension. Microvolt EMG readings showed significant reduction in hyperactive muscle contractures and an immediate expansion of joint range of motion toward normal across acute and chronic pain conditions.

LifeWave Scientific Study by Means of an NM4 Gauge.pdf

Study Title: Nanoscale Wearable Devices Reduce Qualitative and Quantitative Measures of Neuromuscular Pain

  • Study Type / Design: Open-label crossover design pilot study.

  • Sample Size & Demographics: 30 adult participants (ages 26–72; male and female) presenting with diverse neuromuscular pain (arthritic, lower back, neck, shoulder, sciatic, sports/car injury).

  • Intervention / Testing Period: IceWave patches applied using the Cross/Clock Method; evaluated pre- and post-patch application.

  • Key Metrics Measured: Electro-Acuscope microcurrent electrical nerve conduction meter (0–100 numerical conductance scale) and Visual Analog Scale (VAS 0–10).

  • Primary Results & Findings: Active patch wear produced a statistically highly significant reduction in both qualitative pain perception (VAS) and quantitative nerve conduction intensity (Acuscope) (\(p < 0.001\), statistical power \(\ge 94%\)). Tissue electrical conductivity changed within 2–5 seconds (shifting 20–30 points), and significant subjective pain relief occurred within 2–5 minutes.

(See Study Report #3: Nanoscale Wearable Devices Reduce Qualitative and Quantitative Measures of Neuromuscular Pain) in...
IceWave Series of 8 Clinical Study Summaries.pdf

Study Title: Investigative Study of Biochemical Effects of LifeWave Patches Using Bio-explorer Technology

  • Study Type / Design: Open-label longitudinal biochemical tracking trial over 12 weeks.

  • Sample Size & Demographics: 10 adult participants (ages 33–70) suffering from chronic low back and cervical pain.

  • Intervention / Testing Period: IceWave patches worn 24 hours/day for 8 weeks (daytime on pain area, nighttime on Kidney 1 point on feet), followed by a 4-week post-treatment washout/follow-up period without patches.

  • Key Metrics Measured: Bioexplorer non-invasive biohumoral analyzer measuring inflammatory biochemical mediators (COX-2, PGE-2, PGF-2, IL-1beta, lactic acid, Substance P, VIP) and Italian Questionnaire of Pain (QUID).

  • Primary Results & Findings: IceWave patch wear produced statistically meaningful reductions in primary inflammatory markers (COX-2, PGE-2, PGF-2, Interleukin-1beta, lactic acid) and pain neuropeptides (Substance P and Vasoactive Intestinal Peptide [VIP]). Biochemical reductions occurred rapidly within the first 3–4 weeks, stabilized through Week 8, and remained fully sustained at Week 12 (4 weeks after patch removal), confirming a lasting anti-inflammatory reset rather than temporary pain masking.

Investigative Study of Biochemical Effects of LifeWave Patches Using Bio-explorer Technology.pdf

Study Title: Summary of IceWave Clinical Research Study – Infrared Imaging (Thermoregulation Trial)

  • Study Type / Design: Controlled thermographic imaging study.

  • Sample Size & Demographics: 30-36 healthy participants presenting with localized hyperthermic or hypothermic pain anomalies.

  • Intervention / Testing Period: Baseline infrared thermography followed by active IceWave patch application over hyperthermic or hypothermic areas; re-imaged 5 to 20 minutes post-application.

  • Key Metrics Measured: High-precision Computerized Medical Infrared Thermal Imaging (°C).

  • Primary Results & Findings: Active patch wear produced a statistically significant local and distal thermoregulating cooling response in hyperthermic inflamed regions (mean pre-patch temperature 31.94°C vs post-patch 30.85°C, mean \(\Delta T = -1.09^\circ\text{C}\), \(p = 0.008\)), while restoring circulation to hypothermic regions within 5–20 minutes.

Summary of IceWave Clinical Research Study – Infrared Imaging (Dr. Dean Clark, Dr. Steve Haltiwanger, & Salvatore Palomares).pdf